The present investigation is concerned with formulation and in-vitro evaluation of mucoadhesive buccal tablets containing anticholesteremic agent. Lovastatin to by-pass the first pass effect and to improve its bio availability with reduction in dosing frequency. The tablets were prepared by direct compression method. Fifteen formulations were developed with varying combinations of polymers like hydroxy propyl methyl cellulose (HPMC) K100M, Poly vinyl pyrrolidine (PVP) k30, Carbopol 934, Sodium carboxy methyl cellulose. The tablets were tested for weight variation, hardness, drug Content, swelling index and in-vitro drug dissolution study. FTIR studies showed no evidence on interactions between drug, polymers, and excipients. The in-vitro release of Lovastatin was performed under sink conditions (Sodium lauryl sulphate (SLS) PH 6.8, 37 ± 0.5ºC, rpm 50) using USP type II rotating paddle method. The best in-vitro drug release profile was achieved with the formulation F5 which contains HPMC 25 mg, CP 12.5 mg and PVP 12.5 mg. The swelling index of formulation F5 was found to be 6.56 and 78.6 respectively. The formulation F5, containing 20 mg of Lovastatin exhibited 12 h sustained drug release i.e. 98.6 % with desired therapeutic concentration.

Epilepsy is characterised by abnormal behaviour which is leading to tonic flexon, tonic extension, clonus and stupor. Many novel therapeutic regimens were used to treat these disorders through different ways including altering neurotransmission, but so far there is no specific treatment approach which is satisfactory to the patients in terms of complete cure. Our approach is to make understand the herbal medicines usage towards epilepsy. The ethanolic plant extract of Gomphrena Serrata at 400mg/kg, 600mg/kg and 800mg/kg were given to albino mice which were treated with maximum electric shock of 30mA current and pentelene tetrazolium in two different techniques. The results with these extract doses showed significant results which indicated decrease in clonic extension and stupor. Whereas there is no decrease in the tonic flexon observed with all doses. All these results were compared with the standard drug Phenytoin at 25mg/kg I.P. However, the ethanolic plant extract of Gomphrena Serrata at 600mg/kg showed marked increase in the therapeutic activity which is equivalent to Phenytoin and can be compared. Apart from these the ethanolic plant extract of Gomphrena Serrata at 400mg/kg, 600mg/kg and 800mg/kg showed significant decrease in the recovery times when compared to control group

No abstract

Drug interaction is defined as the clinical or pharmacological response occurs when two drugs administered simultaneously, results in beneficial or harmful effects in a person. Based upon mechanism of action drug interactions are classified in to three typ interactions, and Pharmaceutical interactions. Based upon severity, drug interactions are classified in to four types: Minor, moderate, major and contraindicated. According to WHO drug interactions are main cause of mortality and morbidity. It has been estimated that prevalence of interactions is estimated to be 1 22% in world. Drug-drug interactions accounted for 1.1% hospital admissions and 0.1% hospital visits.Polypharmacy, Age, Prescribing errors, some drug-drug interactions. These interactions lead to misinterpretation, alteration of affinity and efficacy of drugs, increased hospital cost, stay and admission, i incidence of adverse events and adverse drug reactions. Clinical pharmacist assisted computerised decision support systems will reduce alert fatigue by pharmacist decision on drug related problems. As these drug interactions effects the safety of patient health care professions should focus on these in clinical settings. echnology, Sri Padmavathi Mahila Viswavidyalayam, Tirupati, Andhra Pradesh Drug interaction is defined as the clinical or pharmacological response occurs when two drugs administered simultaneously, results in beneficial or harmful effects in a person. Based upon mechanism of action drug interactions are classified in to three types: Pharmacokinetic interactions, Pharmacodynamic interactions, and Pharmaceutical interactions. Based upon severity, drug interactions are classified in to four types: Minor, moderate, major and contraindicated. According to WHO drug interactions are main cause of mortality and morbidity. It has been estimated that prevalence of interactions is estimated to be 1 drug interactions accounted for 1.1% hospital admissions and 0.1% hospital visits. Polypharmacy, Age, Prescribing errors, some departments and some disease conditions are the reasons for drug interactions. These interactions lead to misinterpretation, alteration of affinity and efficacy of ital cost, stay and admission, increased morbidity and mortality incidence of adverse events and adverse drug reactions. Clinical pharmacist assisted computerised decision support systems will reduce alert fatigue by pharmacist decision on drug -drug interactions to avoid drug rug interactions effects the safety of patient health care professions should focus on these in clinical settings. interactions, Morbidity, Mortality, Adverse effects, Polypharmacy Drug interaction is defined as the clinical or pharmacological response occurs when two drugs administered simultaneously, results in beneficial or harmful effects in a person. Based upon mechanism of es: Pharmacokinetic interactions, Pharmacodynamic interactions, and Pharmaceutical interactions. Based upon severity, drug interactions are classified in to four types: Minor, moderate, major and contraindicated. Acc...

Hyperlipidaemia is an condition that increases the chance of coronary heart disease (CHD) and atherosclerotic disease (ASHD) in blood vessels. Hyperlipidaemia occurs in response to smoking, obesity, sedentary lifestyle, and other risk factors to extend CHD. Cardiovascular disease (CVD) is the reason for death. Hyperlipidaemia is divided into two broad classifications: Primary (familial) and Secondary (acquired). Primary hyperlipidemia has been generated by hereditary defects and climatic factors or by undisclosed mechanisms. Secondary hyperlipidemia concern to the metabolic disorders linked with the diabetes mellitus, liver complication, thyroid, and kidney complications. Hyperlipidemia also refers to as elevated levels of lipids within the blood. Circulating lipid are carried in lipoproteins that transport the lipids to varied tissues for energy use, lipid deposition, hormone production, and steroid formation. The lipoprotein consists of esterified and unesterified cholesterol, triglycerides, phospholipids, and protein. The general public who have hyperlipidemia experience no symptoms. Hyperlipidemia is most oftenly correlated with high-fat diets, a stationary lifestyle, obesity and diabetes mellitus. Four different classes of cholesterol-lowering drugs namely, statins, niacin, resins, and fibrates are available to treat hyperlipidemia; however, statins are now considered to be the first line therapy. The preventable causes of hyperlipidemia can include: Smoking, Being overweight, Physical inactivity, Steroid use, Alcohol consumption & Diet high in saturated fat, & cholesterol such as cheese, meat, fried & processed foods and egg yolk. The treatment of hyperlipidemia includes statins, bile acid sequestrants, fibric acids, niacin, and cholesterol absorption inhibitors. There are some of the novel drugs which are selected for the treatment of hyperlipidemia which includes: Evolocumab, Alirocumab, Bempedoic acid, Lomitapide, Evinacumab, and Sebelipase alfa.